Parathyroid hormone (PTH) is the major determinant of serum calcium ion (Ca 2+ ) levels, and serum levels of PTH are regulated by the extracellular calcium-sensing receptor (CaSR) Abstract | The ability to monitor changes in the ionic composition of the extracellular environment is a crucial feature that has evolved in all living organisms. The cloning and characterization of the extracellular calcium-sensing receptor (CaSR) from the mammalian parathyroid gland in the early 1990s provided the first description of a cellular, ion-sensing mechanism. This finding demonstrated how cells can detect small, physiological variations in free ionized calcium (Ca 2+ ) in the extracellular fluid and subsequently evoke an appropriate biological response by altering the secretion of parathyroid hormone (PTH) that acts on PTH receptors expressed in target tissues, including the kidney, intestine, and bone. Aberrant Ca 2+ sensing by the parathyroid glands, as a result of altered CaSR expression or function, is associated with impaired divalent cation homeostasis. CaSR activators that mimic the effects of Ca 2+ (calcimimetics) have been designed to treat hyperparathyroidism, and CaSR antagonists (calcilytics) are in development for the treatment of hypercalciuric disorders. The kidney expresses a CaSR that might directly contribute to the regulation of many aspects of renal function in a PTH-independent manner. This Review discusses the roles of the renal CaSR and the potential impact of pharmacological modulation of the CaSR on renal function.
1
. The CaSR can detect minor changes in serum Ca 2+ levels, and the amount of Ca 2+ influx as a result of CaSR activation subsequently feeds back to alter the level of PTH secretion. Serum PTH levels are inversely associated with the extracellular Ca 2+ level. Serum Ca 2+ <1.1-1.2 mmol/l promotes PTH release, which results in reabsorption of Ca 2+ by the kidney, Ca 2+ absorption in the intestine (via 1α-hydroxylation of 25(OH)D 3 into 1,25(OH) 2 D 3 by the kidney proximal tubule), and Ca 2+ resorption from bone 2 . Serum Ca 2+ levels >1.2 mmol/l have the opposite effect; Ca 2+ binding at the CaSR elicits a G q G-protein cascade that activates the phospholipase C pathway and prevents exocytosis of PTH. This event is accompanied by an increase in cytosolic Ca 2+ that has been released from intracellular stores 1, 2 . Defective Ca 2+ sensing by the parathyroid glands, due to altered CaSR expression or function, results in altered divalent cation homeostasis, which can lead to notable, long-lasting morbidity in patients if left untreated 2 . Pharmacological modulators of the CaSR have been developed to correct both hyperparathyroidism and hypoparathyroidism (BOX 1) . Calcimimetic drugs (such as cinacalcet) have been developed to rectify abnormal CaSR expression or function and have been successfully administered to patients for >10 years to treat hyperpara thyroidism secondary to kidney failure 3 . AMG416 is a long-acting peptide that functions as a CaSR agonist and is suitable for intravenous administration. Promising data was obtained from a phase II clinical trial that evaluated AMG416 for the treatment of secondary hyperparathyroidism in patients undergoing haemodialysis 4 . A phase III trial is now complete and met its primary and secondary end points, but the data are yet to be published 5 . CaSR antagonists (calcilytics) are also being investigated for the treatment of autosomal dominant hypocalcaemia with hypercalciuria due to genetic mutations that result in hyperactivation of the CaSR 6 . The combined use of detection methods with enhanced sensitivity (such as branched DNA in situ hybridization or proximity ligation assay), the development of pharmacological CaSR modulators (calcilytics and calcimimetics), and tissue-specific gene ablation studies have markedly enhanced our understanding of the role of the CaSR in the kidney. This Review will address the intrarenal distribution of the CaSR, the potential roles of this receptor in the kidney, and implications of the use of pharmacological CaSR modulators on renal function. The hypothesis that the CaSR might 1 mediate the sensitivity of cyclic adenosine monophosphate (cAMP)-linked hormones to adenylyl cyclase type 6 (ADCY6) will also be discussed.
Renal control of extracellular Ca

2+
The kidney has an important role in the homeostasis of extracellular Ca 2+ levels, and urinary Ca 2+ excretion is proportional to the filtered Ca 2+ load. An increase in serum Ca 2+ results in an increase in urinary Ca 2+ excretion -an effect that can occur in the absence of the Ca 2+ -regulating hormones PTH and active vitamin D (1,25(OH) 2 D 3 ). A number of studies have shown that the kidney is a calcium-sensing organ owing to its ability to sense changes in both urine and serum Ca 2+ levels, and a direct role for the CaSR has been proposed in renal Ca 2+ handling 7 . Familial hypocalciuric hypercalcaemia (FHH) is an autosomal dominant disease caused by mutations that inactivate the CASR gene and manifests as hypercalcaemia, parathyroid hyperplasia, and inappropriately normal or even low urinary Ca 2+ (REF. 8 ). A seminal study that preceded the molecular identification of the CaSR investigated the effects of PTH on urinary Ca 2+ excretion in patients with FHH with hypoparathyroidism as a result of parathyroidectomy, and compared their physiologic response following Ca 2+ infusion to that elicited by hypoparathyroid patients without FHH 9 . Ca 2+ clearance in those with FHH was lower than that recorded in those without FHH upon intravenous Ca 2+ infusion, and this difference was retained in the presence of acetazolamide -a diuretic that inhibits carbonic anhydrase in the proximal tubule, resulting in suppression of proximal tubule solute transport. Interestingly, a greater calciuric response was observed in patients with FHH compared to those without FHH upon administration of etacrynic acid, a loop diuretic. These data suggest that the thick ascending limb (TAL) of the loop of Henle is the predominant site for abnormal renal Ca 2+ transport in patients with FHH 9 . Another study investigated the effect of acute and chronic CaSR inhibition on serum Ca 2+ levels in thyropara thyroidectomized rats in the presence or absence of PTH infusion. Data showed that the CaSR directly participates in the control of extracellular Ca 2+ levels via TAL-mediated regulation of paracellular Ca 2+ transport.
Specifically, chronic CaSR inhibition increased tubular Ca 2+ reabsorption and increased blood Ca 2+ concentration without affecting intestinal Ca 2+ reabsorption or bone resorption 10 . Evidence also suggests that the CaSR can directly regulate Ca 2+ and Mg 2+ permeability via several members of the claudin family (CLDN) of tight junction proteins, including CLDN14 (REFS 11, 12) , CLDN16, and CLDN19 (REF. 13 ). In addition to the TAL, various cell types of the proximal tubule, collecting duct, and juxtaglomerular apparatus also reportedly exhibit Ca 2+ sensitivity 14 , as will be discussed in more detail below.
CaSR expression in the kidney
Determining the exact intrarenal distribution of the CaSR is crucial to our understanding of its functional role in the kidney, but the data accumulated thus far has been controversial and hindered by the lack of suitably sensitive methods required for detecting low levels of CaSR expression. Although CaSR expression in cells of the para thyroid glands or the TAL of the kidney is unrefuted, CaSR expression in other tubular and glomerular cells of the kidney has been a subject of debate. Inconsistent findings have been ascribed to differences in the model systems used, methodological approach, and molecular tools employed. One study performed immunohisto chemistry using commercial and custom antibodies directed against the amino terminus, carboxy-terminus and the entire CaSR protein to investigate the intrarenal distribution and physiology of the CaSR in the human, rat and mouse kidney 15 . Sensitive and specific detection methods (namely branched DNA in situ hybridization and proximity ligation assays) were used to determine the exact cellular localization of the CaSR mRNA and protein (TABLE 1) . The study found that the CaSR is expressed across the entire length of the nephron, with the highest expression within the TAL. Expression was also found in cells of the collecting duct, but with differences in the strength of the immunoreactivity signal and in the cellular polarity (apical, basolateral, or intracellular). Intrarenal CaSR protein expression was not detected in mice with targeted ablation of CaSR in the kidney tubules. Proximity ligation assays in the mouse and rat kidney confirmed the expression of the CaSR within the glomerulus and the proximal tubule, which were previously two sites of major controversy. This expression pattern was confirmed across the three species studied, but marked variation in the overall expression levels and in the nature of the biochemical species (CaSR monomer versus dimer) was observed. These observations have helped clarify the intrarenal distribution of the CaSR, which will not only enable further elucidation of the role of the CaSR in the kidney but also inform on the potential therapeutic use and effects of pharmacological CaSR modulators in these regions.
The glomerulus
As mentioned above, expression of the CaSR in the glomerulus has been reported with inconsistent findings 16, 17 . The proximity ligation assay described above demonstrated low, but above background expression in mouse, rat, and human glomeruli, in both podocytes and mesangial cells 15 . Marked differences in the expression levels
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, and Pi transport in the proximal tubule by integrating multiple inputs from divalent cation concentration, osmolarity, and urine acidification • Calcimimetics would be expected to increase urinary Ca 2+ excretion by acting on the CaSR in the parathyroid glands and the kidney • Calcilytics represent a novel, promising avenue for the treatment of hypercalciuria, nephrolithiasis, and nephrocalcinosis • The CaSR and adenylyl cyclase type 6 are co-expressed in the nephron and act to sensitize hormones to extracellular Ca 2+ and counteract hormone-induced increases in cAMP were observed even within adjacent glomeruli of the same kidney, which could be ascribed to differences in the functional status of the cells 15 . These observations, together with the very low CaSR expression levels, could account for some of the discrepant reports of CaSR expression in the glomerulus.
Evidence for a role for the CaSR in the regulation of glomerular function has derived from studies in which glomerular damage was induced in mice and rats using puromycin aminonucleoside (PAN) 17 . Expression of the CaSR was found in cultured murine podocytes, where calcimimetics prevented PAN-induced apoptosis and cytoskeletal damage in vitro 18 . Administration of a calcimimetic to rats also prevented PAN-induced proteinuria and glomerulosclerosis 18 . Other studies have shown that calcimimetics can decrease the progression of renal damage by preventing podocyte loss and interstitial fibrosis in uninephrectomized, apolipoprotein E-deficient mice 19 . The effects of the calcimimetic were observed in the absence of changes in serum PTH or systemic blood pressure, suggesting a direct involvement of the glomerular CaSR.
In 
Juxtaglomerular apparatus
Numerous stimuli (such as a reduction in blood pressure or reduced luminal NaCl concentration) can activate cells of the juxtaglomerular apparatus to secrete renin, largely by increasing the intracellular cAMP pool 21 . Acute activation of the CaSR with a calcimimetic can inhibit renin secretion, as shown in vitro in cultured mouse primary juxtaglomerular cells, and in vivo 22 . A rise in intracellular Ca 2+ generally promotes exocytosis in secretory cells, whereas an increase in extracellular Ca 2+ in cells of the juxtaglomerular apparatus suppresses renin secretion via CaSR-mediated activation of G q protein, which results in intracellular Ca 2+ mobilization -a phenomenon known as the 'calcium paradox' (REF. 23 ). An increase in extracellular Ca 2+ also leads to suppression of the intracellular cAMP pool by activating calciumregulated adenylyl cyclase type 5 (ADCY5), ADCY6, and phosphodiesterases 24 .
In contrast to what has been observed in acute settings, chronic calcimimetic treatment had no effect on either baseline or stimulated plasma renin activity in rats in vivo 22 . If these observations were to translate to humans, they would suggest that long-term calcimimetic treatment would be unlikely to markedly affect renin plasma levels.
Proximal tubule
PTH, acting through the parathyroid hormone/ parathyroid hormone-related peptide 1 receptor 25 , has a crucial role in regulating inorganic phosphate (Pi) transport in the proximal tubule. The CaSR is expressed apically in the proximal tubules of the mouse, rat and human kidney 7, 15, 26 , and CaSR expression was retained in conditionally immortalized proximal tubular epithelial cells obtained from the urine of a healthy individual 27 . In addition to the well established systemic effects of calciotropic hormones, accumulating evidence suggests the existence of a renal feedback loop that integrates the actions of the CaSR, PTH, and 1,25(OH) 2 D 3 to provide rapid and local control of Ca 2+ and Pi homeostasis (FIG. 1a) . Data gathered from studies performed in isolated S3 segments of the proximal tubule suggest that activation of the CaSR can directly and rapidly blunt the phosphaturic action of PTH, thereby modulating the inhibitory effect of PTH on Pi absorption 26 . On the other hand, chronic high dietary Pi intake or acute PTH administration in vivo can suppress proximal tubule CaSR expression 28 . 
Calcimimetics
Calcimimetics enhance CaSR sensitivity to extracellular Ca 2+ and reduce serum parathyroid hormone (PTH) levels by activating the CaSR that is expressed in the parathyroid gland and the kidney. Two types of calcimimetics have been developed: type I calcimimetics are inorganic or organic polycationic agonists, and type II calcimimetics are positive allosteric enhancers of CaSR activity. Cinacalcet is a type II calcimimetic that has been approved for the treatment of advanced secondary hyperparathyroidism, a common complication of end-stage renal disease. A phase III trial aimed at evaluating the novel calcimimetic peptide, AMG416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease undergoing haemodialysis met its primary and secondary end points.
Calcilytics
Calcilytics are allosteric antagonists of the CaSR that evoke a rightward shift in the Ca 2+ concentration-response curve at the CaSR, such that higher than normal Ca 2+ levels are required to suppress PTH release. Owing to their ability to evoke oscillating fluctuations in serum PTH (a known bone anabolic stimulus), calcilytics such as ronacaleret 94 , and JTT-305 (also known as encaleret) 95 were initially developed to treat age-related osteoporosis. Although their development has been halted due to lack of efficacy, they could be repurposed to treat hypercalciuric disorders caused by an overactive CaSR.
Adverse effects
The CaSR is expressed in numerous tissues, and therefore, the potential adverse effects of systemic CaSR allosteric modulators cannot be ignored. As an example, cinacalcet normalizes serum PTH and calcium concentrations in kidney transplant recipients; however, long-term treatment with cinacalcet might increase urinary calcium excretion and the risk of renal calcium deposits and could alter renal graft function. Conversely, calcilytics are expected to reduce urinary calcium excretion, and might be used to treat gain-of-function variants of the CaSR associated with hypercalciuria and stone diseases. However, an undesired effect would be the stimulation of PTH release, which might worsen hypercalciuria. cells 29 and studies performed in mice lacking both the CaSR and Pth genes showed that the CaSR mitigates the calcaemic response to 1,25(OH) 2 D 3 in vivo 30 . As these studies were carried out in the context of Pth gene deficiency, it was concluded that the exaggerated calcaemic response to 1,25(OH) 2 31 . These data were demonstrated by varying the luminal Ca 2+ concentration in vivo following micropuncture of the mouse proximal tubule as well as in vitro in isolated and cultured mouse proximal tubules that were perfused with various luminal Ca 2+ concentrations 31 . The proximal tubule is responsible for ~65% of fluid reabsorption via transcellular and paracellular routes. The sodium-hydrogen exchanger 3 (SLC9A3) is crucial for fluid reabsorption and proton secretion. Activation of SLC9A3 leads to interstitial Na + accumulation, with a local increase in its osmolarity. This process drives para cellular water reabsorption, as well as reabsorption of solutes (including Ca 2+ ) in a process known as solvent drag. CaSR activation in the proximal tubule drives Na + transport, which is likely to occur by activation of SLC9A3; this effect would result in an increase in fluid and solute reabsorption. PTH also induces natriuresis and diuresis by promoting the internalization of SLC9A3 and the sodium-dependent phosphate transport protein 2A (SLC34A1), via cAMP-protein kinase A (PKA) stimulation 32 . Activation of the apical CaSR could counteract these actions, which would result in increased Ca 2+ and fluid reabsorption. These observations suggest that in the proximal tubule, the CaSR can directly fine tune the actions of PTH, and thereby directly control Ca 2+ and Pi reabsorption -an effect that is independent of systemic changes in calciotropic hormones (FIG. 1a) . These actions of the CaSR can be over-ridden by systemic changes in serum PTH or Pi, which selectively downregulate CaSR expression in the proximal tubule 28 .
Thick ascending limb
The TAL is responsible for the reabsorption of ~25% of filtered Ca 2+ , largely by the cortical TAL (CTAL) but also to some extent by the medullary TAL; the reabsorption of Ca 2+ is coupled with the reabsorption of NaCl 33 . PTH stimulates renal tubular Ca 2+ reabsorption in the TAL by increasing transcellular and paracellular Ca 2+ permeability 10, 34 . In the CTAL, an increase in peritubular Ca 2+ suppresses a PTH-induced increase in intracellular cAMP 35 . CaSR activation in the CTAL also decreases hormone-stimulated (calcitonin, glucagon, vasopressin) intracellular cAMP accumulation by inhibiting ADCY6 (REF. 36 ). Paracellular Ca 2+ permeability is reliant upon the uptake of NaCl across the luminal membrane of this segment, which occurs via the solute carrier family 12 member 1 (SLC12A1) -a bumetanide-sensitive, kidney specific Na-K-Cl symporter. K + ions that are transported into the cell by SLC12A1 are recycled back into the lumen through the apical 70-pS K + channel, of which the renal outer medulla K + (ROMK) channel is a component. Intracellular Na 2+ and Cl − are extruded basolaterally via the Na-K-ATPase and voltage-gated chloride channel protein (CLCNKB) 37 . Together, these processes establish a positive transepithelial potential difference, which provides the driving force for passive reabsorption of monovalent and divalent cations (Na The 70-pS K + channel is formed of ROMK2 (a 30-pS channel) and other subunits that remain to be defined 38 . An increase in peritubular Ca 2+ or Mg 2+ activates the basolateral CaSR, which has been shown in micro dissected TALs from the rat to directly inhibit the 70-pS apical K + channel via cytochrome p450 and cause an increase in 20-hydroxyeicosatetraenoic acid production 39 (FIG. 1b) .
Whether CaSR activation also leads to inhibition of apical K + entry via ROMK2 is currently unknown. Because K + recycling is the rate-limiting step for SLC12A1 activity, such an effect would be expected to result in an abrogation of the driving force for paracellular cation reabsorption. In addition, CaSR activation in isolated rat kidney TALs inhibits the basolateral 50-pS ATP-sensitive inward rectifier K + channel 10 (KCNJ10), which results in inhibition of basolateral K + recycling and transepithelial cation transport 40 . Evidence that such a mechanism occurs in vivo is, however, currently lacking.
CaSR regulation of paracellular permeability. Direct effects of the CaSR on paracellular permeability have been postulated as calcimimetics and calcilytics affect PTH-stimulated Ca 2+ reabsorption in the absence of changes in the transepithelial membrane potential 41 . Hypercalcaemia-mediated polyuria (that occurs during nephrogenic diabetes insipidus) mimics the effects caused by loop diuretics that target SLC12A1, and affected patients exhibit a Bartter-like phenotype with hypokalaemia, hyper-reninaemia with secondary hyperaldosteronism, and metabolic alkalosis 42 . Indeed, type 5 Bartter syndrome can also be present in a subset of individuals with autosomal dominant hypocalcaemia with hypercalciuria caused by activating CaSR mutations 43 . This condition shares many of the phenotypic hallmarks of Bartter syndrome types 1 and 2, which are caused by mutations in the genes encoding SLC12A1 and ROMK, respectively 44, 45 (FIG. 1b) .
Tissue-specific gene ablation and pharmacological studies, as well as observations in patients carrying activating or inactivating mutations in the CaSR gene, have unanimously demonstrated a primary role for the CaSR renal in the control of urinary Ca 2+ excretion 41 . Paracellular permeability in the TAL is controlled by CLDN14, CLDN16, and CLDN19 -all of which have been associated with hypercalciuria, nephrolithiasis, and reduced bone mineral density in humans [11] [12] [13] . CLDN16 and CLDN19 heterodimerize to form a CLDN14-gated pore, through which divalent cations can be reabsorbed. CLDN14 expression increases with high dietary Ca via a calcineurin-nuclear factor of activated T cell (NFATc1)-microRNA (miR)-based transcriptional mechanism, as well as through chromatin remodelling. These events occur downstream of CaSR activation in the TAL. The CaSR controls the transcription of miR-9 and miR-374, which target the 3ʹ-untranslated region of CLDN14 (REF. 13 ). Ciclosporin, a calcineurin inhibitor, prevents CaSR-dependent regulation of CLDN14 and urinary Ca 2+ excretion 13 (FIG. 1b) . Physiologically, the CaSR-CLDN14 axis in the TAL prevents Ca 2+ overload in the presence of elevated serum Ca 2+ levels, but disturbances in this process could contribute to pathological hypercalciuria and nephrocalcinosis, as will be described in more detail below. Furthermore, analysis of a CaSRspecific deletion in the entire murine kidney tubule found that loss of renal CaSR expression results in hypocalciuria that is not accompanied by notable changes in serum and urinary Mg 2+ excretion 47 . These knockout mice exhibited normal serum Ca 2+ and PTH levels, indicating that the predominant role of the renal CaSR is to inhibit Ca 2+ reabsorption in a PTH-independent fashion. This effect is accounted for, at least in part, by increased contribution of the paracellular pathway, as evidenced by concomitant downregulation of CLDN14 and activation of SLC12A1 (REF. 47 ). Calcimimetic drugs would be expected to increase urinary Ca 2+ output via PTH-dependent and PTH-independent (renal CaSR-mediated) actions, and could potentially increase the risk of Ca 2+ stone formation. While it is known that a single dose of a calcimimetic can increase urinary Ca 2+ excretion in renal transplant patients with secondary hyperparathyroidism 48 and that clinical use of calcimimetics does not seem to elicit polyuria or renal Na + wasting, the effect of calcimimetics or calcilytics on nephrolithiasis remains to be investigated.
Distal convoluted tubule
The DCT is a short segment of the nephron that has a key role in fine-tuning Ca 2+ and Mg 2+ reabsorption. Apical Ca 2+ reabsorption occurs through the transient receptor potential cation channel subfamily V member 5 (TRPV5), and is transported across the basolateral membrane by the plasma membrane Ca 2+ -transporting ATPase, ATP2B2, and the sodium-calcium exchanger 1, SLC8A1 (REFS 49, 50 2+ from the pre-urine without affecting Na + reabsorption, thus minimizing renal calcium wasting. However, this concerted interplay is unlikely to prevent the hypercalciuric effect of loop diuretics, or the effect of activating CaSR mutations. Moreover, the CaSR has been shown to interact with the K + channel KCNJ10 that is expressed on the basolateral membrane of the DCT; this interaction causes inactivation of KCNJ10, which in turn could reduce K + recycling through the basolateral Na-K-ATPase thereby contributing to the inhibition of Na + reabsorption in this segment 52 (FIG. 1c) .
Collecting duct
CaSR expression is found along the entire length of the collecting duct, from the cortex to the medulla 14, 15 . The CaSR is expressed in intercalated cells and principal cells of the cortical collecting duct 14, 15 (FIG. 1d) . The CaSR exhibits a predominant apical distribution in the intercalated cells and it has been suggested from studies performed in dissected mouse outer medullary collecting ducts that high activation of the CaSR due to high extracellular Ca 2+ promotes urine acidification through stimulation of the luminal H + -ATPase 54 . Data suggest that formation of alkaline urine predisposes to urolithiasis 55, 56 . Of note, Trpv5 −/− mice are hypercalciuric and polyuric with increased urinary acid excretion and therefore, do not exhibit renal calcification because of this marked urine acidification 54 . When acidification is prevented by targeted gene ablation of the collecting duct-specific B1 subunit of the renal H + -ATPase in Trpv5 −/− mice, notable tubular precipitation of calcium + recycling -the rate-limiting step for Na-K-Cl cotransporter (SLC12A1) activity. This effect leads to a loss of the driving force for paracellular cation reabsorption. Thus, hypercalcaemia mimics the effects of loop diuretics and recapitulates Bartter syndrome types 1 and 2 phenotypes, ascribed to mutations in the genes encoding SLC12A1 and ROMK, respectively. This effect is also mimicked by activating mutations in the CaSR gene that causes type 5 Bartter syndrome with hypercalciuria, hypokalaemic alkalosis and hyper-reninaemic hyperaldosteronism. Bartter syndrome types 3 and 4 are caused by mutations in the genes encoding the basolateral Cl − channel, CLCKB, or its auxiliary subunit, Barttin, respectively. CaSR activation also directly regulates paracellular permeability via NFATc1-miRNA-CLDN14 signalling. c | CaSR in the distal convoluted tubule (DCT). At the apical membrane, the CaSR is biochemically associated with the 1,25(OH) 2 D 3 -regulated transient receptor potential cation channel subfamily V member 5 (TRPV5). Increased Ca 2+ delivery to the DCT results in CaSR activation and increased apical Ca 2+ entry via TRPV5. Intracellularly, calbindin-D28K (CALB1) delivers Ca 2+ to the basolateral membrane where Ca 2+ exits the cell via active mechanisms (ATP2B1 and SLC8A1). The CaSR also decreases the surface expression of the K + channel KCNJ10, which results in inhibition of NaCl 2 reabsorption. d | CaSR in the collecting duct. In the presence of an antidiuretic stimulus, Ca 2+ concentrations in the pre-urine can become super-saturating, potentially leading to Ca 2+ stone formation. When the luminal Ca 2+ concentration becomes critically high it activates the apical CaSR which, in principal cells, blunts vasopressin-mediated apical insertion of the aquaporin 2 (AQP2) water channel and the rate of water reabsorption. In intercalated cells, CaSR activation leads to luminal acidification. Overall, these two effects result in the production of a dilute, acidified urine, which reduces the risk of nephrolithiasis. 20-HETE, 20-hydroxyeicosatetraenoic acid; ATP2B1, plasma membrane calcium-transporting ATPase 1; AQP, aquaporin; AVP, arginine vasopressin; Cld, claudin; miRNA, microRNA; NFAT, nuclear factor of activated T cells; SLC8A1, sodium-calcium exchanger 1; SLC12A3, solute carrier family 12 member 3; PTH1R, parathyroid hormone 1 receptor; SLC4A4, sodium bicarbonate cotransporter 1. ◀ phosphate crystals occurs and animals die prematurely of hydronephrosis, likely due to the presence of renal stones 54 . The CaSR is localized to the apical membrane of the principal cells and is colocalized with the aquaporin 2 (AQP2) water channel in intracellular vesicles 14, 57, 58 . Several in vitro, in vivo, and human observational studies have suggested that CaSR signalling inhibits vasopressin-induced trafficking and expression of AQP2 . A postulated mechanism for this process is that the actions of vasopressin to promote water reabsorption from the lumen causes an increase in urinary Ca 2+ concentration as a consequence of urine concentration, which in turn activates the CaSR located on the apical membrane of the principal cells. The activation of the CaSR reduces the vasopressin-stimulated insertion of AQP2 into the plasma membrane and the rate of water reabsorption, leading to the formation of dilute urine, and consequently a reduced risk of Ca 2+ supersaturation 62, 65, 68 . Studies performed in cultured renal cells and microdissected collecting ducts have demonstrated that the inhibitory effect of CaSR signalling on AQP2 trafficking to the plasma membrane is mainly due to a strong reduction in cAMPinduced AQP2 phosphorylation at serine 256 and AQP2 traffic k ing, resulting in blunting of the osmotic waterpermeability response 66 . Although evidence is building for the effects of extracellular Ca 2+ or calcimimetics (either luminal or basolateral) on renal physiology (TABLE 2) , further studies are necessary to determine the relevance of the interplay between the CaSR and AQP2 in humans and the possibility of using CaSR modulators to rectify severe hypercalciuria and nephrocalcinosis 69 .
Ca
2+
-mediated inhibition of cAMP CaSR and ADCY6 co-expression Evidence that the CaSR and ADCY6 are co-expressed in the same cells in defined nephron segments has led to the hypothesis of a functional interplay between CaSR signalling and inhibition of intracellular cAMP content in response to an increase in extracellular Ca ), and modulation of its function by pH and nutrients, results in adjustment of intracellular cAMP levels 36, 66, 72 ; these data suggest that the CaSR converts an extracellular Ca 2+ stimulus into a negative feedback signal on G s protein-linked hormones that act via cAMP. Given the co-expression of the CaSR and ADCY6 in the same cells of defined nephron segments, it can be speculated that the negative feedback of CaSR signalling on hormones acting through the G s -ADCY6-cAMP pathway confers high sensitivity of hormone effects to changes in Ca
.
Co-expression in the juxtaglomerular apparatus.
Activation of the CaSR in renal juxtaglomerular cells stimulates intracellular Ca 2+ -mediated decreases in cAMP content and inhibition of renin release through activation of ADCY5 and ADCY6 (REFS 24, 73) . In the proximal tubule, PTH increases Pi excretion by stimulating the internalization of SLC34A1 and solute carrier family 23 member 3 (SLC23A3) Na + -dependent Pi transporters from the apical plasma membrane via activation of ADCY6 through PTH type 1 receptors associated with the cAMP-PKA signalling pathway 70 . Evidence that ADCY6 is the adenylyl cyclase isoform that mediates this effect is based on data derived from Adcy6 −/− mice, which displayed Pi wasting and no response to PTH in terms of Pi excretion and urinary cAMP excretion 70 . These data suggest that in the proximal tubule, ADCY6 modulates acute PTH-stimulated cAMP formation and urinary Pi excretion. In this scenario, CaSR in the proximal tubule could represent a major regulator of PTH action by antagonizing its effects on Pi excretion through downregulation of the G s -ADCY6-cAMP pathway (FIGS 1a,2).
Co-expression in the TAL. As discussed, the main function of the CaSR in the TAL is the regulation of urinary Ca 2+ excretion, which has a crucial effect on Ca 2+ balance. Here, SLC12A1 and ROMK work in concert to establish lumen-positive transepithelial potential differences that enable Ca 2+ reabsorption via the paracellular pathway 14 . The trafficking and activity of SLC12A1 is positively regulated by phosphorylation at serine 126 under vasopressin action 74, 75 . Studies performed in Adcy6 −/− mice identified ADCY6 as the isoform that mediates the vasopressininduced phosphorylation of SLC12A1 at serine 126, which is not phosphorylated in knockout mice 71 .
Other studies performed in microdissected CTAL have shown that the CaSR and ADCY6 are co-expressed within the same cells and that activation of the CaSR by extracellular Ca 2+ induces a dose-dependent inhibition of intracellular cAMP content that results from both stimulation of cAMP hydrolysis and inhibition of cAMP synthesis 36 . This effect on intracellular cAMP associated with CaSR signalling in the TAL indicates that CaSR activation impairs vasopressin action in this region, which results in changes in the transepithelial potential due to changes in ion transport as well as regulation of the expression of proteins that compose the tight junctions, including claudins. The CaSR would be expected to counteract PTHinduced Ca 2+ reabsorption in the TAL through a similar signal transduction pathway. Antagonizing the action of vasopressin and PTH through impairment of the G s -ADCY6-cAMP pathway results in a reduction in Ca 2+ reabsorption and an increase in Ca 2+ excretion (FIGS 1b,2 ).
Co-expression in the collecting duct. Although a minimal amount of Ca 2+ is transported in this segment, the extent of water reabsorption and urine acidification can profoundly modify Ca 2+ solubility and, therefore, can increase the risk of Ca 2+ stone formation. Both ADCY3 and ADCY6 are expressed in collecting duct principal cells and have both been suggested to contribute to the overall rise in cAMP during vasopressin stimulation 76 ; however, several lines of evidence suggest that ADCY6 is the predominant enzyme that modulates vasopressin-regulated water reabsorption [77] [78] [79] . Collecting duct-specific knockout of Adcy6 in mice results in a urinary concentration defect associated with reduced vasopressin-stimulated cAMP accumulation 80 ; therefore, Ca 2+ sensing in the collecting duct by the CaSR might sensitize vasopressin to luminal Ca 2+ , which would result in an attenuation of the antidiuretic response to limit water reabsorption (FIGS 1d,2) . In line with this view, data from cultured renal cells and microdissected mouse collecting ducts showed that the negative feedback of CaSR signalling on vasopressin action is primarily due to a reduction in the hormone-dependent generation of cAMP and possibly a reduction in cAMP hydrolysis 66 . Overall, the emerging concept is that within the nephron, co-expression of CaSR and Ca 2+ -inhibitable ADCY6 elicits a negative feedback on the hormones that act through the G s -ADCY6-cAMP pathway to confer high sensitivity of hormone effects to the extracellular Ca 2+ concentration. This negative feedback mainly relies on inhibition of intracellular cAMP levels as a result of CaSR activation by extracellular Ca 2+ and consequent inhibition of cAMP synthesis by ADCY6 (FIG. 2) .
CaSR and nephrolithiasis
The CaSR in the TAL inhibits paracellular Ca 2+ reabsorption by activating CLDN14 transcription, which blocks the paracellular cation channel that is composed of CLDN16 and CLDN19 and is crucial for Ca 2+ and Mg 2+ reabsorption 11 . The CaSR also decreases the activity of SLC12A1, which is usually required for sustaining the electrochemical gradient and drives paracellular divalent cation reabsorption 46 . CaSR activation by serum Ca 2+ in the TAL, therefore, promotes calciuria. Conversely, activation of the CaSR in the proximal tubule antagonizes the phosphaturic action of PTH and promotes proton secretion through SLC9A3 26, 31 , whereas in the collecting duct, CaSR activation decreases water reabsorption by inhibiting the tubular response to vasopressin and increases proton excretion by stimulating proton pump activity 54, 66 . CaSR activity in the proximal tubule and collecting duct can, therefore, counterbalance the risk of calcium phosphate precipitation that is associated with the ability of the CaSR to enhance Ca 2+ excretion in the TAL.
Based on these described findings, both the CaSR and CLDN14 have been investigated as two important loci for kidney stone disease. Allelic variants in both the CaSR and CLDN14 have a known association with nephrolithiasis [81] [82] [83] [84] [85] [86] , but data obtained by several groups have produced contrasting results. In seven French families with familial calcium nephrolithiasis 87 , and in a large group of 359 Canadian sibling pairs 88 , no evidence was found that linked mutations in the CaSR to an increased risk of renal stones. Other researchers, however, have shown that singlenucleotide polymorphisms (SNPs) in the CaSR gene are associated with nephrolithiasis and kidney stones. An association between the CaSR Arg990Gly polymorphism and primary hypercalciuria was found to be more frequent in hypercalciuric patients that formed calcium stones compared to normocalciuric patients who formed stones or healthy individuals 89 . Subsequent in vitro data indicated that the Arg990Gly polymorphism results in a gain-of-function of the CaSR 89 .
Other investigators, however, have found no association between this polymorphism and indices of serum Ca 2+ homeostasis 90 . Calcium nephrolithiasis was also found to be associated with the rs6776158 SNP that is located within the first promoter region of the CaSR gene 91 . In vitro studies showed that the minor G allele at rs67780158 caused a decrease in the transcriptional efficiency of the first promoter in two renal cell lines 91 . Moreover, data indicate that the simultaneous presence of both rs1501899 and the Arg990Gly polymorphism might potentiate the risk of forming kidney stones in patients with primary hyperparathyroidism, despite their apparently opposite effects on CaSR function in the kidney 92 . Carriers of the Arg990Gly polymorphism exhibit increased Ca 2+ excretion, which is expected to predispose to intratubular precipitation of calcium phosphate crystals 89 . Conversely, the rs6776158 -mediated decreases in cAMP content and inhibits renin release through activation of adenylyl cyclase type 5 (ADCY5) and type 6 (ADCY6) 24, 73 . In the proximal tubule, the CaSR is expressed on the luminal membrane and its activation impairs the action of parathyroid hormone (PTH) by antagonizing its effects on Pi excretion through downregulation of the G s -ADCY6-cAMP pathway 70 . This effect reduces Pi excretion and thus limits the risk of formation of calcium-phosphate precipitates. In the thick ascending limb (TAL), CaSR signalling counteracts the action of vasopressin on activation of Na-K-Cl cotransporter (SLC12A1) phosphorylation, causing changes in transepithelial potential resulting in overall reduced Ca 2+ reabsorption. In this segment, ADCY6 is activated by vasopressin 71 . Using a similar signal transduction pathway, the CaSR is expected to counteract PTH-induced Ca 2+ reabsorption in the TAL. In the distal convoluted tubule CaSR might antagonize PTH-induced activation of Ca 2+ reabsorption by TRPV5 via a cAMP-PKA cascade 49 . In the collecting duct ADCY6 is activated by vasopressin 77, 80 . Stimulation of the CaSR by luminal Ca 2+ reduces the vasopressin-stimulated insertion of aquaporin 2 (AQP2), which leads to the formation of dilute urine and favours the solubility of calcium-phosphate salts 66 . The negative feedback of the CaSR on hormones acting through the G s -ADCY6-cAMP pathway is principally caused by the inhibition of cAMP synthesis by the Ca 2+ -inhibitable ADCY6 as a consequence of a CaSR-activated increase in intracellular Ca 2+ concentration. G s , G s α subunit; TRPV5, transient receptor potential cation channel subfamily V member 5.
SNP is associated with decreased CaSR expression and might, therefore, improve tubular efficiency to reabsorb Ca 2+ . This effect could lead to an increase in Ca 2+ concentration in the interstitium, which would increase the risk of hydroxyapatite precipitation in the Randall plaque followed by precipitation of urinary calcium oxalate and formation of calcium-oxalate stones. Deficient expression of the CaSR might also impair CaSR-associated urine acidification and dilution in the collecting duct, and promote Pi retention in the proximal tubule. This effect would expose patients to the risk of calcium phosphate precipitation in the tubular fluid. More recently, a genome-wide association study of kidney stone disease identified an interesting association with rs762468[A] in the first intron of the CaSR gene 93 . Based on these data, CaSR polymorphisms should be considered to be risk factors that predispose individuals to form kidney stones and might be provide potential genetic markers to identify patients at risk of developing calcium nephrolithiasis.
Claudins are a key component of the paracellular pathway. Studies investigating the physiological function of claudins have highlighted a functional interaction between CaSR signalling and claudin gene expression, suggesting a role for claudins in nephrolithiasis. Defects in claudin function have been implicated in patients with hypercalciuria and nephrolithiasis 85 . In the TAL, the CLDN16 channel provides cation permeability in the tight junction that is essential for Ca 2+ and Mg 2+ reabsorption driven by a lumen-positive transepithelial potential gradient 85 . Conversely, CLDN14 blocks the paracellular cation channel that is composed of both CLDN16 and CLDN19 (REF. 11 ). The identification that stimulation of CaSR signalling in the TAL downregulates miR-9 and miR-374 to cause an increase in CLDN14 levels, which in turn suppresses the permeability of the CLDN16 and CLDN19 channels and promotes Ca 2+ excretion, strongly supports a role for claudins in nephrolithiasis 85 .
Conclusions
Numerous studies have shown that the CaSR is expressed along all segments of the nephron, from the glomerulus to the inner medullary collecting ducts.
Interestingly, notable differences in the level of CaSR expression along the nephron have been identified, with the highest expression in the TAL and the lowest in the glomerulus and proximal tubule. Accordingly, direct roles for the CaSR in the kidney have been proposed in these regions and seem to correlate with the expression levels of this receptor. In the TAL, the CaSR is a major determinant of urinary Ca 2+ excretion. In other regions the CaSR acts to fine-tune and integrate multiple stimuli that derive from Na + , pH and mineral ion metabolism, thus setting the sensitivity threshold for several cAMP-coupled hormones to extracellular Ca 2+ . The CaSR can be the target for therapeutic intervention for a number of inherited and acquired conditions, whereby the level of expression and/or function of the CaSR is altered
. Calcimimetics are effective in treating primary and secondary hyperparathyroidism. Calcilytics might be used in the future to treat hypoparathyroidism and, in hypercalciuric patients that form calcium stones, to prevent nephrolithiasis and nephrocalcinosis. Evidence that clinical use of calcimimetics is not associated with either increased urine output or acidification is somewhat unexpected and remains to be fully understood. Immunolocalization studies of the renal CaSR have demonstrated that species differences cannot account for the discrepancies between observations made in humans with genetic CaSR mutations and their murine orthologues. Thus, while the direct contribution of the renal CaSR in preventing hypercalcaemia is undisputed, the precise role of the CaSR in Na 2+ and urine outputs and urine acidification needs to be investigated further to discriminate between the CaSR-dependent and CaSRindependent effects of extracellular Ca
2+
. Finally, the effect of chronic calcimimetic and calcilytic treatment on nephrolithiasis and nephrocalcinosis remains to be assessed. The next challenge will be to identify molecules that specifically target the renal CaSR. Availability of these compounds will help with the development of CaSR-based therapeutics for treating hypercalciuric disorders and will provide a better understanding of the mechanisms that underpin abnormal Ca 2+ handling by the kidney.
